|
The CYPHER® Stent has been used successfully in the United States for more than five years. Development of the CYPHER® Stent began in 1995 with the creation of a Stent Therapeutics Team. Over the next five years, this team collaborated with internal and external Johnson & Johnson partners to develop a therapeutic strategy for the prevention and treatment of restenosis. They identified a number of promising drug candidates and examined a wide variety of polymeric materials and stent coating processes.
Extensive preclinical testing and safety data eventually led to the creation of the polymer coating for the CYPHER® Stent that slowly releases sirolimus into the artery wall over 90 days.
In 2000, the CYPHER® Stent team began the RAVEL Trial, the first multi-center, double-blind, randomized trial in history for drug-eluting stents. Results from the trial surpassed expectations, and two years later the CYPHER® Stent was introduced in Europe.
As the first drug-eluting stent, the CYPHER® Stent has been used by more doctors in more patients than any other drug-eluting stent. And in studies conducted all over the world, its safety and effective performance continues to be proven. Again and again.
Explore this interactive timeline to discover highlights.
| 